SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (1106)8/26/1998 7:39:00 PM
From: Russian Bear  Read Replies (1) of 1826
 
Thanks, Richard.

Area? It must be in square meters of surface area?! What an unwieldy convention!

As a quick and dirty approximation, let's assume that the typical individual has 6 liters of blood, and a surface area of 1.3 square meters. These numbers lead to the following implication: MGI-114 shows in-vitro GI50 effects at dosages of only approximately 2.2% of MTD. (I realize that my methodology is completely unsound, but it does give an intuitive "feel" for the relative amounts of drug required and tolerated.)

Your point about the active transport mechanism is probably much more salient than the futile exercise, above. The leukemia cells, without active transport, require concentrations some three orders of magnitude greater than the average across all cell lines. Very impressive, at least to this layman.

Thanks again,
RB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News